Project dates: June 2013 - May 2020
This study evaluated the effectiveness of extended naltrexone (XR-NTX) in a large urban jail setting, enrolled otherwise out-of-treatment individuals just as they leave jail and return to the community, when they are at high risk for relapse to heroin and illicit opioids and HIV/HCV risk behaviors, including drug injection and unsafe sex. The study compared participants receiving naltrexone to those receiving methadone maintenance at jail release in order to compare extended naltrexone to the current standard-of-care.Abstract on NIH RePORTER
Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: An in-depth qualitative study
Addiction Science and Clinical Practice, 17 (1), 4. doi: 10.1186/s13722-022-00288-4. PMCID: PMC8800291.
Lee JD, Malone M, McDonald R, Cheng A, Vasudevan K, Tofighi B, Garment A, Porter B, Goldfeld KS, Matteo M, Mangat J, Katyal M, Giftos J, MacDonald R (2021).
Comparison of treatment retention of adults with opioid addiction managed with extended-release buprenorphine vs daily sublingual buprenorphine-naloxone at time of release from jail
JAMA Network Open, 4 (9), e2123032. doi: 10.1001/jamanetworkopen.2021.23032. PMCID: PMC8427378.
Velasquez M, Flannery M, Badolato R, Vittitow A, McDonald RD, Tofighi B, Garment AR, Giftos J, Lee JD (2019).
Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
Addiction Science and Clinical Practice, 14 (1), 37. doi: 10.1186/s13722-019-0166-0. PMCID: PMC6771097.